Compass Therapeutics
CMPX
72 hedge funds and large institutions have $267M invested in Compass Therapeutics in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 7 closing their positions.
243% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 7
136% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 11
31% more funds holding
Funds holding: 55 → 72 (+17)
1.14% more ownership
Funds ownership: 63.26% → 64.41% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
34% less capital invested
Capital invested by funds: $401M → $267M (-$135M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$5.63M |
| 2 |
Millennium Management
New York
|
+$3.52M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$2.66M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.87M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.7M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$3.61M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.73M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.65M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$1.49M | -311,500 | Closed |
|
|
SCM
77
Silverarc Capital Management
Boston,
Massachusetts
| – | -$1.35M | -268,307 | Closed |
|
|
MFS
78
Mirabella Financial Services
London,
United Kingdom
| – | -$153K | -30,444 | Closed |
|
79
Osaic Holdings
Scottsdale,
Arizona
| – | -$1K | -100 | Closed |
|
CMPX Hedge Fund Activity: Q1 2023 in Review
72 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q1 2023, worth a combined $267M — down 34% from $401M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CMPX positions and 7 closed out — a net gain of 17 holders — while 26 added to existing stakes and 11 trimmed.
The largest buyer was Braidwell, adding an estimated $5.63M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $4.7M sold.
- 72 institutional investors held Compass Therapeutics (CMPX) as of Q1 2023, up from 55 in Q4 2022.
- Funds reported $267M of Compass Therapeutics stock for Q1 2023, down 34% quarter-over-quarter.
- 24 funds opened new Compass Therapeutics positions in Q1 2023 and 7 closed out, a net change of +17 holders.
- The largest Compass Therapeutics buyer in Q1 2023 was Braidwell, an estimated $5.63M added.
- The largest Compass Therapeutics seller in Q1 2023 was Eventide Asset Management, an estimated $4.7M sold.
Based on aggregated 13F filings for Q1 2023.